NASDAQ:RTRX - Retrophin Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$30.94 -0.66 (-2.09 %)
(As of 07/20/2018 04:54 AM ET)
Previous Close$31.60
Today's Range$30.54 - $31.61
52-Week Range$19.57 - $31.87
Volume282,700 shs
Average Volume326,231 shs
Market Capitalization$1.20 billion
P/E Ratio-21.07
Dividend YieldN/A
Beta1.06
Retrophin logoRetrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase I clinical trial for the treatment of phenylketonuria; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in Phase III clinical trial for the treatment of primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RTRX
CUSIPN/A
Phone760-260-8600

Debt

Debt-to-Equity Ratio0.15
Current Ratio5.07
Quick Ratio4.98

Price-To-Earnings

Trailing P/E Ratio-21.07
Forward P/E Ratio-18.20
P/E GrowthN/A

Sales & Book Value

Annual Sales$154.94 million
Price / Sales7.98
Cash FlowN/A
Price / CashN/A
Book Value$7.46 per share
Price / Book4.15

Profitability

EPS (Most Recent Fiscal Year)($1.50)
Net Income$-59,730,000.00
Net Margins-41.95%
Return on Equity-20.27%
Return on Assets-11.80%

Miscellaneous

Employees173
Outstanding Shares39,940,000
Market Cap$1,200.32

Retrophin (NASDAQ:RTRX) Frequently Asked Questions

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin Inc (NASDAQ:RTRX) announced its quarterly earnings results on Tuesday, May, 1st. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.25. The biopharmaceutical company earned $38.43 million during the quarter, compared to analysts' expectations of $39.32 million. Retrophin had a negative net margin of 41.95% and a negative return on equity of 20.27%. The company's revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.01 earnings per share. View Retrophin's Earnings History.

When is Retrophin's next earnings date?

Retrophin is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Retrophin.

What price target have analysts set for RTRX?

1 analysts have issued 12-month price targets for Retrophin's shares. Their forecasts range from $43.00 to $43.00. On average, they expect Retrophin's share price to reach $43.00 in the next twelve months. This suggests a possible upside of 39.0% from the stock's current price. View Analyst Ratings for Retrophin.

What is the consensus analysts' recommendation for Retrophin?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Retrophin's key competitors?

Who are Retrophin's key executives?

Retrophin's management team includes the folowing people:
  • Mr. Stephen J. Aselage, Chief Exec. Officer, Pres & Director (Age 67)
  • Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 59)
  • Mr. Neil F. McFarlane, Chief Operating Officer (Age 45)
  • Ms. Elizabeth E. Reed, Sr. VP, Gen. Counsel & Corp. Sec. (Age 47)
  • Dr. William E. Rote, Sr. VP of R&D (Age 55)

Has Retrophin been receiving favorable news coverage?

News stories about RTRX stock have been trending somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Retrophin earned a media sentiment score of 0.11 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 49.67 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Retrophin's major shareholders?

Retrophin's stock is owned by a number of of retail and institutional investors. Top institutional investors include Boston Advisors LLC (0.50%), Handelsbanken Fonder AB (0.41%), Bank of Montreal Can (0.40%), Fisher Asset Management LLC (0.17%), Hartford Investment Management Co. (0.02%) and FNY Investment Advisers LLC (0.01%). Company insiders that own Retrophin stock include Alvin Shih, Elizabeth E Reed, Neil F Mcfarlane, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.

Which major investors are selling Retrophin stock?

RTRX stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Bank of Montreal Can. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Neil F Mcfarlane and William E Rote. View Insider Buying and Selling for Retrophin.

Which major investors are buying Retrophin stock?

RTRX stock was acquired by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Boston Advisors LLC, Hartford Investment Management Co. and FNY Investment Advisers LLC. View Insider Buying and Selling for Retrophin.

How do I buy shares of Retrophin?

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Retrophin's stock price today?

One share of RTRX stock can currently be purchased for approximately $30.94.

How big of a company is Retrophin?

Retrophin has a market capitalization of $1.20 billion and generates $154.94 million in revenue each year. The biopharmaceutical company earns $-59,730,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Retrophin employs 173 workers across the globe.

How can I contact Retrophin?

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]


MarketBeat Community Rating for Retrophin (NASDAQ RTRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  430
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.